Medtronic plc 's MDT brain therapy business gets a boost with the recent FDA approval for the company's latest Deep Brain Stimulation (DBS) Clinician.

Medical tech company Medtronic has just landed FDA clearance on its Deep Brain Stimulation (DBS) Clinical Programmer and ActivaProgramming application. "This marks a new era of innovation from the ...

--Medtronic plc today announced the U.S. launch of its advanced Patient Programmer technology for Deep Brain Stimulation therapy at the Samsung Developers Conference in San Jose, Calif. Food and ...

Having to manually program settings can be a time-consuming process. Medtronic’s SureTune2 aims to alleviate some of the frustrations of this process. Using visualization of patient-specific ...

To help clinicians and patients better optimize the therapy, Medtronic sought user-friendly mobile devices to adjust the programming of DBS implants and to put more control into the patient’s hands.

The U.S. FDA approval also includes the Medtronic BrainSense™ Electrode Identifier (EI), which helps reduce patient time spent in clinic to program their DBS settings.

The SenSight directional DBS lead system works seamlessly with certain Medtronic neurostimulators, including the recently-approved Percept™ PC neurostimulator.

Medtronic Percept™ DBS therapy is the only sensing-enabled † DBS system available, allowing a physician to use data from a patient’s brain activity to personalize their treatment.

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy personalization and clinic efficiency.

Medtronic has recalled the auto-registration feature in the StealthStation deep brain stimulation (DBS) software because of inaccuracies during DBS procedures, according to a notice on the US Food ...